



07049092

[Note: Form 19b-4(e) will not appear in the Code of Federal Regulations.]

For Internal Use Only See File No. 91 - **91-1587** Submit 1 Original and 9 Copies

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 19b-4(e)

OMB Approval No.: 3235-0504
Expires: 07/31/2001
Estimated average burden hours per response: 12:00

SECURITIES AND EXCHANGE COMMISSION
DIVISION OF MARKET REGULATION
MAR 13 2007

Information Required of a Self-Regulatory Organization Listing and Trading a New Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Part I Initial Listing Report

- Name of Self-Regulatory Organization Listing New Derivative Securities Product:
New York Stock Exchange LLC
- Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):
Open-end Management Investment Company
- Class of New Derivative Securities Product:
Investment Company Units (Exchange-Traded Funds)
- Name of Underlying Instrument:
HealthShares Autoimmune-Inflammation Index
- If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:
Narrow-Based
- Ticker Symbol(s) of New Derivative Securities Product: HHA (for HealthShares Autoimmune-Inflammation Exchange-Traded Fund)
- Market or Markets Upon Which Securities Comprising Underlying Instrument Trades: NYSE, Nasdaq, Stockholm, SWX Elec (Switzerland), Copenhagen, London
- Settlement Methodology of New Derivative Securities Product:
Regular way trade settle on T+3/Book-entry only held in DTC
- Position Limits of New Derivative Securities Product (if applicable):
Not applicable

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:
Mary Yeager

Title:
Assistant Corporate Secretary

Telephone Number:
(212) 656-2222

Manual Signature of Official Responsible for Form:
Mary Yeager

Date: March 12, 2007

PROCESSED
APR 09 2007
THOMSON FINANCIAL

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	MAR 13 2007

Mary Yeager
Assistant Secretary

New York Stock Exchange LLC
11 Wall Street
New York, NY 10005



SECURITIES AND EXCHANGE COMMISSION
RECEIVED

tel: 212.656.2062
fax: 212.656.3939
myeager@nyse.com

MAR 13 2007
DIVISION OF MARKET REGULATION

March 12, 2007

Gail Jackson
Paralegal Specialist
Division of Market Regulation
Securities and Exchange Commission
100 F Street, NE – Room 6628
Washington, DC 20549

Re: Forms 19b-4(e) for HealthShares Autoimmune-Inflammation Exchange-Traded Fund

Dear Ms. Jackson:

Pursuant to Rule 19b-4(e) under the Securities Exchange Act of 1934, New York Stock Exchange LLC ("Exchange") encloses for filing one original and nine copies of a Form 19b-4(e) for:

- HealthShares Autoimmune-Inflammation Exchange-Traded Fund (HHA).

This Fund began trading on the Exchange on a fully listed basis on March 12, 2007. The New York Stock Exchange's rules for listing and trading products of this nature are found in Section 703.16 of the Exchange's Listed Company Manual.

Sincerely,

A handwritten signature in cursive script, appearing to read 'Mary Yeager', written in black ink.

Enclosure

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	MAR 13 2007

END